This database contains 25 studies, archived under the term: "levels"
Click here to filter this large number of results.
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.; Design: Double-blind, placebo-controlled clinical trial.; Setting: Academic medical centers.; Participants: Subjects with mild to moderate Alzheimer disease.; Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C […]